Regeneron Pharmaceuticals Inc. (REGN) is facing an important deadline, as investors who have lost money are being urged to contact Glancy Prongay Murray LLP about a securities fraud lawsuit. The lawsuit alleges that the company made false and misleading statements regarding the safety and efficacy of its flagship drug. Investors who suffered losses are recommended to seek legal counsel and potentially join the class action against Regeneron Pharmaceuticals Inc.

Go to REGN Page

Investor opinions & comments

To leave a comment, you need to Login or Register.

There are no comments yet. Be the first to leave one!

Other Data for REGN

Regeneron Pharmaceuticals Inc. REGN Leads Biotech Industry with Innovative Drug Developments

January 18, 2026

Regeneron Pharmaceuticals Inc. REGN Receives Positive Opinion from European Medicines Agency

October 31, 2025

Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance

September 5, 2025

Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals

July 5, 2025

Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target

June 27, 2025

REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 33.76% Profit Margin

June 5, 2025

Related Data

Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit

February 2, 2025

Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report

January 22, 2025

Regeneron Pharmaceuticals Faces Securities Class Action After 9 Billion Value Loss

January 23, 2025

Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit

January 12, 2025

Analyst Cuts Regeneron Pharmaceuticals REGN Price Target After Sales Concerns and Investor Lawsuit Hagens Berman

February 13, 2025

Search on StockPrognosis.com

Sections of the site

Deadline Alert: Regeneron Pharmaceuticals Inc. REGN

Investor opinions & comments

Other Data for REGN

Related Data